Conatus Pharmaceuticals (CNAT) Tops Q2 EPS by 8c

Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q2 EPS of ($0.30), $0.08 better than the analyst estimate of ($0.38).

Cash, cash equivalents and marketable securities were $30.2 million at June 30, 2016, compared with $36.5 million at December 31, 2015. The company believes current financial resources are sufficient to maintain operations and ongoing clinical trials for at least the next 12 months.

For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Reading (RDI) Tops Q2 EPS by 4c